Work

Supplementary Figures from PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide

Year: 2023

Type: supplementary-materials

Abstract: Figure S1. A compound screen identifies Volasertib as potently cytotoxic to MSH6-deficient glioblastoma cells. Figure S2. The effects of temozolomide and PLK1 inhibitors on glioblastoma cells with and without MSH6 knockdown. Figure S3. Combination of Volasertib and temozolomide on glioblastoma cells with and without MSH6 knockdown. Figure S4. PLK1 inhibitor effects in orthotopic glioblastoma models. Figure S5. In vitro PLK1 inhibitor effects on normal astrocytes and glioblastoma cells. Figure S6. Myc expression and PLK1 inhibitor effects.

DOI: 10.1158/1535-7163.22505719

Authors: Fumi Higuchi, Alexandria L. Fink, Juri Kiyokawa, Julie J. Miller, Mara V.A. Koerner, Daniel P. Cahill, Hiroaki Wakimoto

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362610034

Cites:

Cited by:

Related to: 10